Jump to content

Talk:Vivek Ramaswamy

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 2600:1014:b05f:669e:84e7:38d6:a1fe:60f3 (talk) at 00:44, 14 February 2023 (→New edit request). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

WikiProject iconBiography Unassessed
WikiProject iconThis article is within the scope of WikiProject Biography, a collaborative effort to create, develop and organize Wikipedia's articles about people. All interested editors are invited to join the project and contribute to the discussion. For instructions on how to use this banner, please refer to the documentation.BiographyWikipedia:WikiProject BiographyTemplate:WikiProject Biographybiography articles
???This article has not yet received a rating on Wikipedia's content assessment scale.

Edit requests from COI editor

I'm a declared COI editor starting to work on Vivek Ramaswamy's page. I have not worked on his page prior to this message. I'm hoping to reshape the page and work with editors to remove the tag. I'm requesting one edit at the moment.

Extended content

Axovant Sciences is one of the many subsidiaries that Vivek founded and it does not make sense to give this priority or for it to have its own sentence. Therefore, I'd like to change the following. I've added references for the three subsidiaries that would be new to the page.

Current wording: He is also the founder of Axovant Sciences, a clinical-stage pharmaceutical company focusing on treatments for dementia, and the founder of other subsidiaries including: Altavant[1], Aruvant[2], Axovant, Datavant, Dermavant, Enzyvant, Myovant, Urovant[3], Genevant[4], Immunovant[5], Metavant[6], and Respivant[7].

Requested wording: He is the founder of many subsidiaries including: Axovant Sciences[1], Altavant[1], Aruvant[2], Axovant, Datavant, Dermavant, Enzyvant, Myovant, Urovant[3], Genevant[4], Immunovant[5], Metavant[6], and Respivant,[7] Sinovant[2], and Alyvant[3].

References

  1. ^ Grover, Natalie. "Acadia drug approval could clear way for Axovant dementia therapy". Reuters. Retrieved 27 January 2019.
  2. ^ Keown, Alex. "Roivant Launches New China-Based Startup Sinovant Sciences". BioSpace. Retrieved 27 January 2019.
  3. ^ Grover, Natalie. "Positive ocular implant data bring Allergan one step closer to NDA; Vivek Ramaswamy spawns another 'Vant'". Endpoints News. Retrieved 27 January 2019.

Thank you for your help, FinalFrontier.003 (talk) 07:23, 27 January 2019 (UTC)[reply]

Reply 27-JAN-2019

Information should not be included in this article solely because it is true or useful. A Wikipedia article should not be a complete exposition of all possible details, but a summary of accepted knowledge regarding its subject.[1] Verifiable and sourced statements should be treated with appropriate weight, whereas the listing of each and every company spun off from Roivant does not merit this added weight — especially since this information is already listed in the Roivant article — which the present article already has WikiLinks to. Regards,  Spintendo  12:33, 27 January 2019 (UTC)[reply]

References

  1. ^ See Wikipedia:Requests for arbitration/Rex071404 § Final decision, which suggested a similar principle in November 2004.


Question about Vivek Ramaswamy page

Moved from User talk:Spintendo
 –  Spintendo  13:51, 15 February 2019 (UTC)[reply]

Hi Spintendo,

I appreciate all of the assistance that you've offered for Roivant Sciences and Vivek Ramaswamy's pages to date. I understand why your most recent edit to Vivek's page, to remove the long list of companies, was made and it certainly made sense. I wanted to get an understanding from you about how to work on the Vivek page to get the tag removed (contributor to this article has a close connection). I wasn't involved with the company when the tag was put on and I work for them with a clear COI - is there a way to move ahead to get it removed? Thanks for your assistance in the matter, FinalFrontier.003 (talk) 07:03, 13 February 2019 (UTC)[reply]

Reply 15-FEB-2019

  • @FinalFrontier.003: It is recommended that, as a courtesy, you first try asking the editor who assigned the template — in this case, the administrator NeilN — in order to find out from them if it can be removed. Since they placed the template, they are in the best position to know whether or not the issues which caused its placement have been corrected. You may contact them by placing a new message on their talk page.
  • In the unlikely event that you do not hear back from them after a reasonable amount of time, please contact me at my talk page or the article's talk page.[a] Thank you!
    Regards,  Spintendo  13:51, 15 February 2019 (UTC)[reply]

Notes

  1. ^ As I do not actively monitor Ramaswamy's talk page, if the message is placed for me here, please also activate a {{request edit}} template on the page in order to notify me or another editor of your message.
thank you @Spintendo:! I'm writing to the other editor now. FinalFrontier.003 (talk) 07:06, 17 February 2019 (UTC)[reply]

Request edit

Hi @Spintendo: I contacted the editor, NeilN, who placed the COI tag on the page and I received this message back on his talk page where I placed my question: "FinalFrontier.003, NeilN is on an extended break from Wikipedia, so he will not see or answer your question. Softlavender (talk) 09:37, 17 February 2019 (UTC)" I am, therefore, asking again if we can discuss having the COI tag removed from this page. The page was tagged almost two years ago and it does not seem to be an issue any longer. I am a declared COI editor working for Vivek only in the last few months. Thanks for any assistance you can offer. FinalFrontier.003 (talk) 10:54, 17 February 2019 (UTC)[reply]

As I see it, the section on the subject's career focuses on the subject's work, particularly, how successful it is. This is information which was added by editors who had not declared a COI but whom a COI is suspected. ( The error is mine: The template is not an undisclosed COI maint. template, but rather, a simple COI template.) As this information still exists in the article, please elaborate upon what it is about the page that seems to no longer warrant the COI tag.  Spintendo  14:13, 18 February 2019 (UTC)[reply]

Content changes for Career section and addition of Recognition section

I am a declared COI editor and I'm working to get the COI tag removed from Vivek's page. I understand that in order to do so, I need to get the language in the career section changed so that it no longer reflects the work that the undeclared COI editor or editors did. I am proposing completely new language for the Career section and an addition of a Recognition section. I appreciate any asisstance editors can offer.

Extended content

1. I would like to propose replacing all content in the career section with this content:

Ramaswamy started his career as a hedge fund manager at QVT Financial in New York and became a partner in 2013.[1][2] In 2014, he founded and became the chief executive officer of Roivant Sciences,[3] a pharmaceutical company that builds drug and health care subsidiaries in various stages of development.[4] In 2015, Forbes estimated that Roivant was worth $3.5 billion.[1] As of late 2018, Ramaswamy and Roivant employed over 750 scientists and executives around the world. [5]

2. In addition, I'd like to create a section below Career called Recognition and add these two sentences there:

Ramaswamy was featured on the cover of Forbes in September 2015.[6] He was part of the Forbes 30 under 30 list[7] and was biopharma’s youngest chief executive when he started Roivant Sciences.[1]

References

  1. ^ a b c Vardi, Nathan. "The 30-Year-Old CEO Conjuring Drug Companies From Thin Air". Forbes. Retrieved 28 February 2019.
  2. ^ Herper, Matthew. "Vivek Ramaswamy's Enzyvant Asks FDA To Approve Treatment For Dying Babies". Forbes. Retrieved 28 February 2019.
  3. ^ Terry, Mark. "Vivek Ramaswamy's Latest "Vant": Aruvant to Focus on Sickle Cell and Beta-Thalassemia". Biospace. Retrieved 28 February 2019.
  4. ^ Mukherjee, Sy. "How a 32-Year-Old CEO Got a Team of Pharma Vets to Join His Radical Approach to Making Drugs". Retrieved 28 February 2019.
  5. ^ Carroll, John. "Vivek Ramaswamy ramps up biotech startup #14 — this time working on a gene therapy for sickle cell disease and β-thalassemia". Endpoints News. Retrieved 28 February 2019.
  6. ^ Ghosh, Ajay. "Entrepreneur Vivek Ramaswamy Featured on Forbes Cover". The Universal News Network. Retrieved 28 February 2019.
  7. ^ "Vivek Ramaswamy". Forbes. Retrieved 28 February 2019.

Thank you, FinalFrontier.003 (talk) 07:05, 28 February 2019 (UTC)[reply]

Just want to clarify that the template in question is not an undisclosed template. It is a simple COI template, so the issue is not about the additions of text from undisclosed editors, but rather, the additions having come from editors who are under a conflict of interest. Sorry if there was confusion over that point.  Spintendo  14:20, 28 February 2019 (UTC)[reply]
 Maintenance template removed  Spintendo  14:33, 28 February 2019 (UTC)[reply]

New edit request

I have one request as a COI editor at this time.

Current wording: In the career section there is a sentence that says "“Ramaswamy worked at QVT Financial from 2007 to 2014, where he was a partner and co-managed the firm’s biotech portfolio.”

Requested addition: After this sentence I'd like to add context to his work there: "During this time, he invested in companies developing antiviral drugs, including for the cure of hepatitis C."[1][2]

I look forward to hearing feedback. FinalFrontier.003 (talk) 07:24, 16 April 2019 (UTC)[reply]

References

  1. ^ Vardi, Nathan. "The 30-Year-Old CEO Conjuring Drug Companies From Thin Air". Forbes. Retrieved 16 April 2019.
  2. ^ Garde, Damian. "One brash idea to save the drug industry — and (maybe) make a few billion dollars". Investor Village. Retrieved 16 April 2019.

Reply 16-APR-2019

  Edit request declined  

  • The provided sources state that the hepatitis C drug was developed through the efforts of 4 entities: William Symonds, Pharmasset, Gilead, and the investments of QVT — of which Ramaswamy was an analyst/partner. The request posits Ramaswamy as partner in QVT as the sole justification for being able to attach his name to that drug's development, while simultaneously discounting (in the requested prose) the roles of the other entities by not mentioning them. Looking at the sources for verification, only Forbes provides somewhat of a timeline — and from that, the salience with which Ramaswamy inbues his role is not evident. That's because his efforts were not in isolation — they occurred concomitant to other entities' roles. A claim to have bankrolled the cure for hep C alone, as this claim is worded, requires exceptional sourcing to verify it.

Regards,  Spintendo  09:38, 16 April 2019 (UTC)[reply]

  • I have been asked to update the page I previously edited. The paid relationship was previously declared and remains on my userpage. The changes will primarily be the addition of new material, including additional publications and expanded book sections, including critical reception. Everything will be extensively sourced. I may also do some reformatting of the Career section for clarity.:


Jhofferman (talk) 06:18, 1 February 2023 (UTC)[reply]

References

Religion

Is Ramaswamy a practicing Hindu? I just read an article that mentioned that he is a vegetarian (as many Hindus are), but the article didn’t explicitly state his religious affiliation. 2600:1014:B05F:669E:84E7:38D6:A1FE:60F3 (talk) 00:44, 14 February 2023 (UTC)[reply]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Vivek_Ramaswamy&oldid=1139222333"